ImpactU - Detalle del Producto

Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going

Acceso Abierto

ID Minciencias: ART-0000205419-218

Ranking: ART-ART_A2

Idioma: Inglés

Publicado: 01/07/2020

APC (est): $1,500 GBP

Abstract:

• Azithromycin (AZM) is a promising drug candidate for the treatment of the COVID-19. • Studies so far on the use of AZM in COVID-19 patients have various methodological limitations. • The evidence on the efficacy of AZM as an adjunct to hydroxychloroquine for COVID-19 is not enough yet. • Combination of AZM and HCQ should be decided with caution due serious cardiac adverse effects. • Currently, 21 clinical trials are being carried out on the use of AZM in COVID-19.

Tópico:

COVID-19 Clinical Research Studies

Citaciones:

Citaciones por año:

Altmétricas:

Información de la Fuente:

FuenteJournal of Global Antimicrobial Resistance	Cuartil año de publicaciónNo disponible	Volumen22
IssueNo disponible	Páginas680 - 684	pISSN2213-7165
ISSNNo disponible	Perfil OpenAlexhttps://openalex.org/S2764745279

Enlaces e Identificadores:

Minciencias ID	ART-0000205419-218	Scienti ID	0000205419-218	Scholar URL	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=info%3AYFUZUzSjlhMJ%3Ascholar.google.com&btnG=
Open_access URL	https://doi.org/10.1016/j.jgar.2020.06.016	Openalex URL	https://openalex.org/W3039413216	Pdf URL	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328586/
Scholar citations URL	https://scholar.google.com/scholar?cites=1411494978355025248&as_sdt=5,44&sciodt=0,44&hl=en	Pmcid URL	https://www.ncbi.nlm.nih.gov/pmc/articles/7328586	Doi URL	https://doi.org/10.1016/j.jgar.2020.06.016
Pmid URL	https://pubmed.ncbi.nlm.nih.gov/32622008

Artículo de revista